Corbus Pharmaceuticals Holdings, Inc. (CRBP), announced Monday the initiation of the multiple ascending dose or MAD portion of its Phase 1 clinical trial evaluating CRB-913, a highly peripherally restricted CB1 inverse agonist, for the treatment of obesity.
The MAD study follows the single ascending dose or SAD phase completed earlier in 2025 and involves once-daily dosing for seven days in healthy volunteers.
The trial focuses on assessing safety, tolerability, and pharmacokinetics or PK of increasing doses.
The company said no treatment-related neuropsychiatric events have been observed till date, even at doses higher than those projected to be clinically effective. The MAD portion is expected to complete in the third quarter 2025.
CRB-913 is a novel oral small molecule designed to target the CB1 receptor with minimal brain penetration, aiming to reduce the neuropsychiatric risks associated with earlier CB1 inverse agonists, while supporting weight loss.
Following the MAD study, Corbus plans to initiate a Phase 1b dose-range finding study in the fourth quarter 2025, with completion expected in the second half of 2026.
Corbus Pharmaceuticals is a clinical-stage company focused on oncology and obesity.
Currently, CRBP is trading at $6.94, down by 5.71 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.